e8vk
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 4, 2008
GENOMIC HEALTH, INC.
(Exact name of registrant as specified in its charter)
         
Delaware
(State or other jurisdiction
of incorporation) 		  000-51541
(Commission
File Number) 		  77-0552594
(IRS Employer
Identification No.)
     
301 Penobscot Drive, Redwood City, California
(Address of principal executive offices) 		  94063
(Zip Code)
Registrant’s telephone number, including area code: (650) 556-9300
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
     On December 4, 2008, the Board of Directors of Genomic Health, Inc. (the “Company”) elected Ginger L. Graham a member of the Board of Directors of the Company. A copy of the Company’s press release announcing Ms. Graham’s election to the Board of Directors as an independent director is attached as Exhibit 99.1 to this report and is incorporated herein by reference.
Item 7.01 Regulation FD Disclosure.
     As disclosed under Item 5.02, on December 4, 2008, the Company’s Board of Directors elected Ginger L. Graham a member of the Board of Directors. The Company’s press release announcing Ms. Graham’s election is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
     (c) Exhibits
         
Exhibit No.   Description
  99.1    
Press release issued by Genomic Health, Inc. dated December 8, 2008

 

 

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: December 8, 2008
         
  GENOMIC HEALTH, INC.
 		  
  By   /s/ G. Bradley Cole    
    Name:   G. Bradley Cole   
    Title:   Executive Vice President, Operations and Chief Financial Officer   

 

 

         
Exhibit Index
         
Exhibit No.   Description
  99.1    
Press release issued by Genomic Health, Inc., dated December 8, 2008